No Data
Shanghai Yizhong: Report of Shanghai Yizhong Pharmaceutical Co., Ltd. for the third quarter of 2024
Shanghai Yizhong Pharmaceutical Co., Ltd. Report for the Third Quarter of 2024
shanghai Yizhong (688091.SH) released its performance for the first three quarters, with a net income of 34.67 million yuan, a 73.46% year-on-year decrease.
Shanghai Yizhong (688091.SH) disclosed its third quarter report for 2024, achieving operating income for the first three quarters...
Shanghai Yizhong (688091.SH): The net income in the first three quarters was 34.67 million yuan, a year-on-year decrease of 73.46%.
Gelonghui, October 28th | Shanghai Yizhong (688091.SH) released its third quarter report, with revenue of 0.17 billion yuan in the first three quarters, a decrease of 39.25% year-on-year, net income of 34.67 million yuan, a decrease of 73.46% year-on-year, non-net profit of 31.08 million yuan, a decrease of 72.39% year-on-year, and basic earnings per share of 0.17 yuan.
Is being included in medical insurance a lifesaving straw? Shanghai Yizhong's core products cannot enter hospitals, investors inquire about the progress of national talks | Direct hitting earnings conference
①Due to the closure of the self-funded pharmacy in the core hospital, Shanghai Yizhong's self-paid product paclitaxel micelles, which are not included in medical insurance, cannot be admitted to the hospital, impacting its performance in the first half of the year. ②Shanghai Yizhong is preparing for the paclitaxel micelles to participate in this year's medical insurance negotiations. In response to this matter, the chairman stated that the national medical insurance negotiation progress for paclitaxel micelles is proceeding normally, and the final negotiation result will be announced in subsequent disclosures.
Yizhong Pharmaceutical Gets Nod For Pancreatic Cancer Drug Trial
No Data
No Data